- Functional Biomarkers
- Up-Regulated Proteins
- Others
Renal Biomarkers Market size was valued USD 1042.1 billion by 2022 and expected to reach USD 1454.08 billion by 2029, at a CAGR of 6.8% from 2023-2029. Renal diseases are one of the major cause of death in geriatric population. Renal biomarkers are measurable indicators used to screening, monitoring, and diagnosing the activity of renal diseases by determining their blood and urine levels. The biomarkers are administered into kidneys to determine the renal functions. The early diagnosis of renal diseases helps to take proper treatment before the irreversible damage of kidneys.
Renal Biomarkers Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
6.8%
Largest Market
North America
Fastest Growing Market
Asia Pacific
Renal Biomarkers Market Dynamics
Increase in the prevalence of renal diseases due to rise in hypertension and diabetes in elderly patients is a major factor fuel the renal biomarkers market. Rise in geriatric population, increase in the R&D for the development of novel renal biomarkers, and using of renal biomarkers in preclinical and clinical trials to determine the safety of new drugs are anticipated to propel the market. However, stringent regulatory scenario, lack of specificity and sensitivity in current renal biomarkers, and lack of favorable reimbursement policies are anticipated to impede the growth of renal biomarkers market.
North-America got significant share
Renal Biomarkers Market Regional Analysis
North America renal biomarkers market is expected to expand at significant CAGR due to its raising ageing population along with increased prevalence of renal disorders. The state-of-art healthcare infrastructure, and favorable reimbursement policies are expected to enhance the growth of renal biomarkers market. The existence of the manufacturers in large number, surge in R&D investments are expected to fuel the growth of market. The well established distribution channels further enhance the growth of the market. Europe market is anticipated to offer enormous opportunities for the market players plunged in market. Asia Pacific market is led by China, Japan, and India due to increasing geriatric population coupled with increased prevalence of renal disorders.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup’s details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Renal Biomarkers Market Segmentation
By Biomarker Type
By Diagnostic Technique
- Particle enhanced turbidimetric immunoassay
- Chemiluminescent enzyme immunoassay
- Enzyme linked immunosorbent assay
- Colorimetric assay
- Liquid chromatography
By End User
- Hospitals
- Outpatient Clinics
- Research Centers
- Diagnostic Labs
By Geography
- Latin America
- Europe
- Asia Pacific
- Middle East
- North America
Frequently Asked Questions
renal biomarkers market size valued USD 1042.1 billion by 2022 and expected to reach USD 1454.08 billion by 2029, at a CAGR of 6.8% during the forecast period 2023-2029
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
| 1.Executive Summary |
| 2.Global Renal Biomarkers Market Introduction |
| 2.1.Global Renal Biomarkers Market - Taxonomy |
| 2.2.Global Renal Biomarkers Market - Definitions |
| 2.2.1.Biomarker Type |
| 2.2.2.Diagnostic Technique |
| 2.2.3.End User |
| 2.2.4.Route of Administration |
| 2.2.5.Region |
| 3.Global Renal Biomarkers Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Renal Biomarkers Market Analysis, 2018-2022 and Forecast 2023-2029 |
| 4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Renal Biomarkers Market By Biomarker Type, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 5.1. Functional Biomarkers |
| 5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Up-Regulated Proteins |
| 5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Others |
| 5.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 6.Global Renal Biomarkers Market By Diagnostic Technique, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 6.1. Particle enhanced turbidimetric immunoassay |
| 6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Chemiluminescent enzyme immunoassay |
| 6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Enzyme linked immunosorbent assay |
| 6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Colorimetric assay |
| 6.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Liquid chromatography |
| 6.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 7.Global Renal Biomarkers Market By End User, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 7.1. Hospitals |
| 7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Outpatient Clinics |
| 7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Research Centers |
| 7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Diagnostic Labs |
| 7.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 8.Global Renal Biomarkers Market By Route of Administration, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 8.1. Injection |
| 8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Nasal Spray |
| 8.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 9.Global Renal Biomarkers Market By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 9.1. North America |
| 9.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.1.3. Market Opportunity Analysis |
| 9.2. Europe |
| 9.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.2.3. Market Opportunity Analysis |
| 9.3. Asia Pacific (APAC) |
| 9.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.3.3. Market Opportunity Analysis |
| 9.4. Middle East and Africa (MEA) |
| 9.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.4.3. Market Opportunity Analysis |
| 9.5. Latin America |
| 9.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.5.3. Market Opportunity Analysis |
| 10.North America Renal Biomarkers Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 10.1. Biomarker Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Functional Biomarkers |
| 10.1.2.Up-Regulated Proteins |
| 10.1.3.Others |
| 10.2. Diagnostic Technique Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Particle enhanced turbidimetric immunoassay |
| 10.2.2.Chemiluminescent enzyme immunoassay |
| 10.2.3.Enzyme linked immunosorbent assay |
| 10.2.4.Colorimetric assay |
| 10.2.5.Liquid chromatography |
| 10.3. End User Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Hospitals |
| 10.3.2.Outpatient Clinics |
| 10.3.3.Research Centers |
| 10.3.4.Diagnostic Labs |
| 10.4. Route of Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Injection |
| 10.4.2.Nasal Spray |
| 10.5. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.5.1.United States of America (USA) |
| 10.5.2.Canada |
| 11.Europe Renal Biomarkers Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 11.1. Biomarker Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Functional Biomarkers |
| 11.1.2.Up-Regulated Proteins |
| 11.1.3.Others |
| 11.2. Diagnostic Technique Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Particle enhanced turbidimetric immunoassay |
| 11.2.2.Chemiluminescent enzyme immunoassay |
| 11.2.3.Enzyme linked immunosorbent assay |
| 11.2.4.Colorimetric assay |
| 11.2.5.Liquid chromatography |
| 11.3. End User Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Hospitals |
| 11.3.2.Outpatient Clinics |
| 11.3.3.Research Centers |
| 11.3.4.Diagnostic Labs |
| 11.4. Route of Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.Injection |
| 11.4.2.Nasal Spray |
| 11.5. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.5.1.Germany |
| 11.5.2.France |
| 11.5.3.Italy |
| 11.5.4.United Kingdom (UK) |
| 11.5.5.Spain |
| 11.5.6.Rest of EU |
| 12.Asia Pacific (APAC) Renal Biomarkers Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 12.1. Biomarker Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Functional Biomarkers |
| 12.1.2.Up-Regulated Proteins |
| 12.1.3.Others |
| 12.2. Diagnostic Technique Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Particle enhanced turbidimetric immunoassay |
| 12.2.2.Chemiluminescent enzyme immunoassay |
| 12.2.3.Enzyme linked immunosorbent assay |
| 12.2.4.Colorimetric assay |
| 12.2.5.Liquid chromatography |
| 12.3. End User Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Hospitals |
| 12.3.2.Outpatient Clinics |
| 12.3.3.Research Centers |
| 12.3.4.Diagnostic Labs |
| 12.4. Route of Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.Injection |
| 12.4.2.Nasal Spray |
| 12.5. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.5.1.China |
| 12.5.2.India |
| 12.5.3.Australia and New Zealand (ANZ) |
| 12.5.4.Japan |
| 12.5.5.Rest of APAC |
| 13.Middle East and Africa (MEA) Renal Biomarkers Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 13.1. Biomarker Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Functional Biomarkers |
| 13.1.2.Up-Regulated Proteins |
| 13.1.3.Others |
| 13.2. Diagnostic Technique Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Particle enhanced turbidimetric immunoassay |
| 13.2.2.Chemiluminescent enzyme immunoassay |
| 13.2.3.Enzyme linked immunosorbent assay |
| 13.2.4.Colorimetric assay |
| 13.2.5.Liquid chromatography |
| 13.3. End User Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Hospitals |
| 13.3.2.Outpatient Clinics |
| 13.3.3.Research Centers |
| 13.3.4.Diagnostic Labs |
| 13.4. Route of Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Injection |
| 13.4.2.Nasal Spray |
| 13.5. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.5.1.GCC Countries |
| 13.5.2.South Africa |
| 13.5.3.Rest of MEA |
| 14.Latin America Renal Biomarkers Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 14.1. Biomarker Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.1.1.Functional Biomarkers |
| 14.1.2.Up-Regulated Proteins |
| 14.1.3.Others |
| 14.2. Diagnostic Technique Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.2.1.Particle enhanced turbidimetric immunoassay |
| 14.2.2.Chemiluminescent enzyme immunoassay |
| 14.2.3.Enzyme linked immunosorbent assay |
| 14.2.4.Colorimetric assay |
| 14.2.5.Liquid chromatography |
| 14.3. End User Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.3.1.Hospitals |
| 14.3.2.Outpatient Clinics |
| 14.3.3.Research Centers |
| 14.3.4.Diagnostic Labs |
| 14.4. Route of Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.4.1.Injection |
| 14.4.2.Nasal Spray |
| 14.5. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.5.1.Brazil |
| 14.5.2.Mexico |
| 14.5.3.Rest of LA |
| 15. Competition Landscape |
| 15.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 15.2.1.Merck Millipore (U.S) |
| 15.2.2.Thermo Fisher Scientific Inc (U.S) |
| 15.2.3.Hoffmann-La Roche Ag (Switzerland) |
| 15.2.4.Abbott Molecular Inc (U.S) |
| 15.2.5.Beckman Coulter Inc (U.S) |
| 15.2.6.Astute Medical Inc (U.S) |
| 15.2.7.Randox Laboratories Ltd (Ireland) |
| 16. Research Methodology |
| 17. Appendix and Abbreviations |
- Merck Millipore (U.S)
- Thermo Fisher Scientific Inc (U.S)
- Hoffmann-La Roche Ag (Switzerland)
- Abbott Molecular Inc (U.S)
- Beckman Coulter Inc (U.S)
- Astute Medical Inc (U.S)
- Randox Laboratories Ltd (Ireland)